Search

everythinglearnresearchcommunity

for

Search:↓

Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Minoxidil and finasteride combo maintains hair density effectively.

A man's skin condition, pemphigus vulgaris, came back after he was treated with interleukin 2 for cancer.

The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.

Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.

Using minoxidil with finasteride in a cream helps maintain hair thickness after stopping oral finasteride.

PDGF signaling is crucial for maintaining and renewing hair follicle stem cells, which could help treat hair loss.

JAGGED1 could help regenerate tissues for bone loss and heart damage if delivered correctly.

Understanding phenotypic plasticity is crucial for developing effective cancer therapies.

The document concludes that specific itchy skin diseases during pregnancy have varying fetal risks and treatments, including corticosteroids and other medications.

Box A of HMGB1 can improve stem cell function, aiding anti-aging therapy.

Adolescents with severe alopecia incur significantly higher healthcare costs.

Platelet-rich plasma therapy may have benefits and is generally safe, but more research is needed to confirm its effectiveness and safety.

Hormone therapy may increase migraines in transgender women and decrease them in transgender men; more research is needed on migraine management in transgender individuals.

Drospirenone is a unique progestin with anti-water retention and potential blood pressure benefits, used in birth control and hormone therapy.

Topical drugs and near-infrared light therapy show potential for treating alopecia.

The document concludes that hormone therapy is essential for treating gender dysphoria, with specific drugs and monitoring protocols recommended for safety and effectiveness.

Testosterone therapy increases bone density in older men with low testosterone levels.

Testosterone therapy is generally safe for transmen, improves sexual function, and has manageable health risks with proper monitoring.

The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

Low-Level Laser Therapy and other light treatments for hair growth lack strong evidence and need more research.

Hormone therapy increases facial and body hair in transgender men, while hair removal improves well-being in transgender women, but cost is a barrier as insurance often doesn't cover it. Dermatologists can use various treatments for these hair issues.

PRP therapy significantly improves hair thickness and density in male pattern baldness.

Regenerated fully functional hair follicles using stem cells, with potential for hair regrowth therapy.

Some drugs may reduce prostatitis symptoms short-term with few side effects.

Skin aging is caused by stem cell damage and can potentially be delayed with treatments like antioxidants and stem cell therapy.

Skin doctors should recognize and treat conditions like hair-pulling and skin-picking early, often using therapy and medication, to help 50-70% of patients.

The document concludes that treating female hair loss should target reducing excess androgen and blocking its effects on hair follicles, with the best treatments being hormonal therapy, adrenal suppression, and topical minoxidil.